+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Myocardial remodelling and matrix metalloproteinases in heart failure: turmoil within the interstitium



Myocardial remodelling and matrix metalloproteinases in heart failure: turmoil within the interstitium



Annals of Medicine 33(9): 623-634



The progression of left ventricular (LV) dysfunction is often accompanied by changes in LV geometry and myocardial architecture that can be defined as LV myocardial remodelling. An important event in LV myocardial remodelling is alterations in the extracellular matrix (ECM). A family of zinc-dependent proteases implicated in facilitating myocardial tissue remodelling by degrading components of the ECM are the matrix metalloproteinases (MMPs). The temporal expression of MMPs and the local tissue inhibitors of MMPs (TIMPs) appear to be differentially regulated in several cardiovascular disease states such as myocardial infarction, LV hypertrophy, and dilated cardiomyopathy. Both pharmacological and genetic modulation of myocardial MMP expression has been demonstrated to alter the course of LV myocardial remodelling and LV dysfunction. The induction of MMPs within the myocardium during the heart failure process probably results in liberation of bioactive molecules, proteolytic degradation of ECM structural proteins, and alterations in cell-cell contact and adhesion. Modifying MMP expression and activation may reduce this turmoil within the myocardial interstitium and, in turn, prove to be a useful therapeutic paradigm for heart failure treatment.

(PDF emailed within 1 workday: $29.90)

Accession: 046753725

Download citation: RISBibTeXText

PMID: 11817657


Related references

Myocardial remodelling and matrix metallotxoteinases in heart failure: turmoil within the interstitium. Annals of Medicine 33(9): 623-634, 2001

Cardiac matrix remodelling in congestive heart failure: the role of matrix metalloproteinases. Clinical and Investigative Medicine. Medecine Clinique et Experimentale 27(2): 93-100, 2004

Inhibition of matrix metalloproteinases An additional effect of ACE inhibitors on cardiac remodelling in heart failure?. European Heart Journal 21(Abstract Suppl.): 465, August-September, 2000

Type-specific dysregulation of matrix metalloproteinases and their tissue inhibitors in end-stage heart failure patients: relationship between MMP-10 and LV remodelling. Journal of Cellular and Molecular Medicine 15(4): 773-782, 2011

Involvement of matrix metalloproteinases in the regulation of myocardial extracellular matrix in patients with congestive heart failure. Zhonghua Yi Xue Za Zhi 86(24): 1693-1696, 2006

Bioactive peptide signaling within the myocardial interstitium and the matrix metalloproteinases. Circulation Research 91(12): 1082-1084, 2002

Matrix Metalloproteinases in Myocardial Infarction and Heart Failure. Progress in Molecular Biology and Translational Science 147: 75-100, 2017

TNF-a and myocardial matrix metalloproteinases in heart failure: relationship to LV remodeling. American Journal of Physiology 282(4): 288-H1295, 2002

TNF-alpha and myocardial matrix metalloproteinases in heart failure: relationship to LV remodeling. American Journal of Physiology. Heart and Circulatory Physiology 282(4): H1288-H1295, 2002

The renin-angiotensin-aldosterone system and myocardial collagen matrix remodelling in congestive heart failure. European Heart Journal 16 Suppl O: 107-109, 1995

Icariin attenuates cardiac remodelling through down-regulating myocardial apoptosis and matrix metalloproteinase activity in rats with congestive heart failure. Journal of Pharmacy and Pharmacology 63(4): 541-549, 2011

Matrix metalloproteinases, tissue inhibitors of metalloproteinases, and heart failure outcomes. International Journal of Cardiology 151(2): 237-239, 2012

Comparative effects of rosuvastatin and allopurinol on circulating levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with chronic heart failure. International Journal of Cardiology 145(3): 438-443, 2011

Role of matrix metalloproteinases and their tissue inhibitors as potential biomarkers of left ventricular remodelling in the athlete's heart. Clinical Science 117(4): 157-164, 2009

From myocardial hypertrophy to heart failure: role of the interstitium. Cardiologia 38(12 Suppl 1): 67-77, 1993